biosimilars

Patients

Biosimilars: Unlocking access, closing the cost divide

Every day, countless Americans are forced to choose between meeting basic needs such as food, housing, or transportation and paying for their medications.

News

Tariffs spelled out with Scrabble letters

Tariffs 'could cancel out discounts with biosimilars'

Tariffs on US pharma imports could remove discounts offered to health systems by biosimilars and threaten the future of the sector, says a non-profit.

News

Cheaper Soliris biosimilars reach the US market

The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand.

News

First biosimilar fast-acting insulin reaches US market

Sanofi has claimed FDA approval for the first biosimilar of Novo Nordisk's rapid-acting insulin analogue Novolog.

News

Hand pointing to viewer through map of China

Trump tariffs 'would strain the pharma supply chain'

Pharma organisations in the US have said that Trump's tariffs plan could drive up the cost of generics, block supply chains and worsen drug shortages.

R&D